China BCT Pharmacy Group, Inc. (CNBI)
China BCT Pharmacy Group, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Liuzhou, CN. The stock last traded at $0.00, up 100.00% on the session, giving a market capitalisation of $686,778. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 8.7%. Its beta of -3.86 implies it has historically moved less than the broad market.
China BCT Pharmacy Group, Inc. functions as a comprehensive pharmaceutical enterprise within the People's Republic of China, conducting its operations through various subsidiary companies. Its business activities are primarily categorized into three distinct divisions: Pharmaceutical Distribution, Retail Pharmacy, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution division procures a diverse array of medicinal goods from various suppliers, subsequently supplying them to a broad client base that includes hospitals, retail drug stores, other wholesale distributors, clinics, medical centers, and individual consumers. Its extensive inventory, numbering approximately 8,000 distinct items, encompasses both branded and generic prescription medications, over-the-counter remedies, traditional Western and Chinese medicines, personal care products, medical supplies, Chinese herbal remedies, and medical instruments. Through its Retail Pharmacy segment, the company manages a network of 196 directly owned pharmacies, predominantly located in Guangxi province, operating under the "Baicaotang" brand. These outlets provide expert pharmaceutical services and offer a broad assortment of health-related products. This range includes prescription and non-prescription drugs, refined and roughly processed traditional Chinese herbal medicines, family planning items, and various other pharmaceutical and healthcare products. The Pharmaceutical Manufacturing division, operating under the "Asio" brand, is responsible for producing and marketing a range of generic and clinical pharmaceuticals. This includes treatments for inflammation and bacterial infections, oncology drugs, cardiovascular medications, and hepatitis therapies. Key products manufactured by the company include Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was originally known as China Baicaotang Medicine Limited before adopting its current name, China BCT Pharmacy Group, Inc., in March 2010. Its corporate headquarters are situated in Liuzhou, People's Republic of China.
China BCT Pharmacy Group, Inc. is most often compared with the following Healthcare names: